Tumor evolutionary analysis and clinical vignettes for patients who derived clinical benefit from palbociclib, everolimus, and exemestane triplet therapy

Analysis of tumor phylogeny and clonal dynamics following CDK4/6i and anti-ER therapy revealed convergent (HER2 activation) and divergent (ER or PI3K/AKT/mTOR activation) paths to treatment resistance in tumors with distinct lineages (A, B). Evolutionary analysis, acquired genomic alterations to prior CDK4/6i, and treatment history is shown for patients with pre-CDK4/6i and post-CDK4/6i (trial baseline) biopsies. A shows convergent evolution of ERBB2 activation in two distinct co-existing tumor lineages (an activating clonal ERBB2L869R mutation and an acquired ERBB2 focal high amplification in 32_T1; an acquired activating high-clonality ERBB2L755S mutation in 32_BB1). B shows an increase in the clonality of an activating ESR1D538G mutation (from subclonal to clonal). C shows a case with two distinct co-existing tumor lineages in its post-CDK4/6i biopsies, each with clonal drivers mutations in divergent pathways (ER pathway with an activating clonal ESR1Y537S,L536P mutation in 22_T1; PI3K/AKT/mTOR pathway with an activating clonal MTORT1977R mutation in 22_BB1). Even though no pre-CDK4/6i biopsy was available for this patient, targeted panel data from other post-CDK4/6i biopsies confirmed the existence of these tumor lineages. In a patient’s tumor phylogenic tree, each subclone is associated with a branch and a color, and this color matches the color in the pie chart that quantifies the relative abundance of each subclone in the tumor. The number of mutations unique to each subclone and known oncogenic mutations are shown next to each branch. Data shown in the clinical vignettes includes the timing of treatments and biopsies, and selected clinical, genomic, and transcriptomic features. Time on treatment for CDK4/6i-containing therapies is included in the figure. Acquired genomic alterations (in A, B) or putatively acquired genomic alterations (in C) following CDK4/6i therapy are shown in red, together with their associated transcriptomic features
Tumor evolutionary analysis and clinical vignettes for patients who derived clinical benefit from palbociclib, everolimus, and exemestane triplet therapy

Publication

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial (2024) Jorge Gómez Tejeda Zañudo, et al. Nat Commun. 2024;15(NA). Figure: F5.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates A1): A1 ncbigene_synonym ADRA1D 146
Homo sapiens Primates PIK3CA PIK3CA ncbigene_symbol PIK3CA 5290
Homo sapiens Primates ERBB2 ERBB2 ncbigene_symbol ERBB2 2064
Homo sapiens Primates BB1, BB1 ncbigene_synonym CD80 941
Homo sapiens Primates BB1, BB1 ncbigene_synonym NMBR 4829
Homo sapiens Primates BB1, BB1 ncbigene_synonym MBOAT7 79143
Homo sapiens Primates KMT2C KMT2C ncbigene_symbol KMT2C 58508
Homo sapiens Primates PI3K PI3K ncbigene_synonym PIK3CB 5291
Homo sapiens Primates PI3K PI3K ncbigene_synonym PIK3CD 5293
Homo sapiens Primates PI3K PI3K ncbigene_synonym PIK3CG 5294
Homo sapiens Primates PI3K PI3K famplex_relations PIK3R3 8503
Homo sapiens Primates PI3K PI3K famplex_relations PIK3R4 30849
Homo sapiens Primates PI3K PI3K famplex_relations PIK3R5 23533
Homo sapiens Primates PI3K PI3K famplex_relations PIK3R6 146850
Homo sapiens Primates PI3K PI3K famplex_relations PIK3R1 5295
Homo sapiens Primates PI3K PI3K famplex_relations PIK3R2 5296
Homo sapiens Primates ESR1 ESR1 ncbigene_symbol ESR1 2099
Homo sapiens Primates AMP AMP ncbigene_synonym APRT 353
Homo sapiens Primates AMP AMP ncbigene_synonym MFAP1 4236
Homo sapiens Primates NF1 NF1 ncbigene_symbol NF1 4763
Homo sapiens Primates mTORC1 MTORC1 famplex_relations MTOR 2475
Homo sapiens Primates mTORC1 MTORC1 famplex_relations RPTOR 57521
Homo sapiens Primates AKT1 AKT1 ncbigene_symbol AKT1 207
Homo sapiens Primates MFT MFT ncbigene_synonym CYLD 1540
Homo sapiens Primates MFT MFT ncbigene_synonym SLC25A32 81034
Homo sapiens Primates (lon). LON ncbigene_synonym LONP1 9361
Homo sapiens Primates (Endo ENDO ncbigene_synonym MANEA 79694
Homo sapiens Primates FGFR FGFR famplex_relations FGFR1 2260
Homo sapiens Primates FGFR FGFR famplex_relations FGFR2 2263
Homo sapiens Primates FGFR FGFR famplex_relations FGFR3 2261
Homo sapiens Primates FGFR FGFR famplex_relations FGFR4 2264
Homo sapiens Primates FGFR FGFR famplex_relations FGFRL1 53834
Homo sapiens Primates TP53 TP53 ncbigene_symbol TP53 7157
Homo sapiens Primates Soft SOFT ncbigene_synonym POC1A 25886

Chemical mentions

Word Match MeSH Name ChEBI
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
Fulvestrant fulvestrant 7alpha-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17beta-diol chebi:31638
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
Fulvestrant fulvestrant 7alpha-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17beta-diol chebi:31638
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
Letrozole letrozole 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile chebi:6413
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
Letrozole letrozole 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile chebi:6413
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
Letrozole letrozole 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile chebi:6413
Everolimus everolimus (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone chebi:68478
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
Palbociclib palbociclib 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one chebi:85993

Disease mentions

Word Match MeSH Name DOID